Diabetes in clinical practice

Diabetes in Clinical Practice

Volumn , Issue , 2010, Pages 1-81

  Fonseca, Vivian A ^a   Pendergrass, Merri ^b   McDuffie, Roberta Harrison ^c  

^a TULANE UNIVERSITY MEDICAL CENTER   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c TULANE UNIVERSITY HEALTH SCIENCES CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84892221032     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-1-84882-103-3     Document Type: Book

References (148)

1. Phillips LS, Branch WT, Cook CB, et al. Clinical inertia. Ann Intern Med 2001; 135(9):825-834.
2. The National Diabetes Education Program. Working together to manage diabetes: a guide for pharmacy, podiatry, optometry, and dental professionals. Available at: http://ndep. nih.gov/diabetes/pubs/PPODprimer-color.pdf. Last accessed September 2007.
3. American Diabetes Association. Standards of medical care in diabetes. Diabetes Care 2007; 30(Suppl 1):S4-S41.
4. Delamater AM. Clinical use of hemoglobin A1c to improve diabetes management. Clin Diabetes 2006; 24:6-8.
5. Heisler M, Vijan S, Anderson RM, et al. When do patients and their physicians agree on diabetes treatment goals and strategies, and what difference does it make? J Gen Intern Med 2003; 18(11):893-902.
6. Bergenstal, RM. Overcoming clinical inertia in diabetes care. Physician's Weekly 2007; 24:1-2.
7. Wagner EH. Chronic disease management: what will it take to improve care for chronic illness? Eff Clin Pract 1998; 1(1):2-4.
8. Landers, SJ. Team effort best way to control diabetes. Available at: www.ama-assn.org/amednews/site/free/hlsb0703.htm. Last accessed September 2007.
9. American Association of Clinical Endocrinologists. State of diabetes in America: a new report reveals America's diabetes health is in jeopardy. Available at: www.aace.com/newsroom/press/2005/index.php/r=20050518-2. Last accessed September 2007.
10. The National Diabetes Education Program. Team care: comprehensive lifetime management for diabetes. Available at: http://ndep.nih.gov/diabetes/ pubs/TeamCare.pdf. Last accessed September 2007.
11. Miller CD, Phillips LS, Tate MK, et al. Meeting American Diabetes Association guidelines in endocrinologist practice. Diabetes Care 2000; 23(4):444-448.
12. Piette JD, Weinberger M, McPhee SJ, et al. Do automated calls with nurse follow-up improve elf-care and glycemic control among vulnerable patients with diabetes? Am J Med 2000; 108(1):20-27.
13. American Diabetes Association. Position Statement: Nutrition Principles and Recommendations in Diabetes. Diabetes Care 2004; 27(Suppl 1):S36.
14. Hensrud DD. Dietary Treatment and Long-Term Weight Loss and maintenance in Type 2 Diabetes. Obes Res 2001; 9(Suppl 4):348S-353S
15. Anderson JW, Randles KM, Kendall CWC, Jenkins DJA. Carbohydrate and fiber recommendations for individuals with diabetes: a quantitative assessment and meta-analysis of the evidence. J Am Coll Nutr 2004; 23(1):5-17
16. Ferrannini E, Camastra S, Gastaldelli A, Sironi AM, et al. Beta cell function in obesity: effects of weight loss. Diabetes 2004; 53:S26-33.
17. Franz MJ, Bantle J P, Beebe CA, et al. Evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes and related complications. Diabetes Care 2002; 25(1):148-98.
18. Kelley DE, Kuller LH, McKolanis TM, et al. Effects of moderate weight loss and orlistat on insulin resistance, regional adiposity, and fatty acids in type 2 diabetes. Diabetes Care 2004; 27(1):33-40
19. Henry RR, Scheaffer L, Olefsky JM. Glycemic effects of intensive caloric restriction and isocaloric refeeding in noninsulin-dependent diabetes mellitus. J Clin Endocrinol Metab 1985; 61:917-925.
20. Kelley DE, Wing R, Buonocore C, et al. Relative effects of calorie restriction and weight loss in noninsulin-dependent diabetes mellitus. J Clin Endocrinol Metab 1993; 77(5):1287-1293.
21. American Diabetes Association. Using the Diabetes Food Pyramid. Available at: http://diabetes. org/nutrition-and-recipes/nutrition/foodpyramid.jsp. Last accessed September 2007.
22. Morrato EH, Hill JO, Wyatt HR, Ghushchyan V, Sullivan PW. Physical activity in U.S. adults with diabetes and at risk for developing diabetes, 2003. Diabetes Care 2007; 30(2):203-9.
23. Snowling NJ, Hopkins WG. Effects of different modes of exercise training on glucose control and risk factors for complications in type 2 diabetic patients: a meta-analysis. Diabetes Care 2006; 29(11):2518-27.
24. Exercise: Calories burned in 1 hour of exercise. Available at: www.mayoclinic.com/health/exercise/SM00109. Last accessed September 2007.
25. Hu G, Jousilahti P, Barengo NC, Qiao Q, Lakka TA, Tuomilehto J. Physical activity, cardiovascular risk factors, and mortality among Finnish adults with diabetes. Diabetes Care 2005; 28(4):799-805.
26. American Diabetes Association. Diabetes mellitus and exercise: position statement. Diabetes Care 2002; 25:S64.
27. American Diabetes Association. Physical activity/exercise and diabetes mellitus. Diabetes Care 2003; 26:S73-S77.
28. Magee MF, Isley WL; BARI 2D Trial Investigators. Rationale, design, and methods for gly-cemic control in the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) Trial. Am J Cardiol 2006; 97:20G-30G.
29. Gerstein HC, Riddle MC, Kendall DM, et al; ACCORD Study Group. Glycemia treatment strategies in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. Am J Cardiol 2007; 99:34i-343i.
30. Nathan DM, Buse JB, Davidson MB, et al. Management of hyperglycemia in type 2 diabetes: A consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2006; 29:1963-1972.
31. Bolen S, Feldman L, Vassy J, et al. Systematic review: comparative effectiveness and safety of oral medications for type 2 diabetes mellitus. Ann Intern Med 2007; 147:386-399.
32. Grant RW, Wexler DJ, Watson AJ, et al. How doctors choose medications to treat type 2 diabetes: a national survey of specialists and academic generalists. Diabetes Care 2007; 30:1448-1453.
33. DeFronzo, RA. Lilly lecture 1987. The triumvirate: beta-cell, muscle, liver. A collusion responsible for NIDDM. Diabetes 1988; 37:667-687.
34. Drucker, DJ. The role of gut hormones in glucose homeostasis. J Clin Invest 2007; 117:24-32.
35. Schmitz O, Brock B, Rungby J. Amylin agonists: a novel approach in the treatment of diabetes. Diabetes 2004; 53(Suppl 3):S233-S238.
36. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998; 352:854-865.
37. DeFronzo RA, Goodman AM. Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus. The Multicenter Metformin Study Group. N Engl J Med 1995; 333:541-549.
38. Goldner MG, Knatterud GL, Prout TE. Effects of hypoglycemic agents on vascular complications in patients with adult-onset diabetes. 3. Clinical implications of UGDP results. JAMA 1971; 218:1400-1410.
39. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998; 352:837-853.
40. Landgraf R, Bilo HJ, Muller PG. A comparison of repaglinide and glibenclamide in the treatment of type 2 diabetic patients previously treated with sulphonylureas. Eur J Clin Pharmacol 1999; 55:165-171.
41. Rosenstock J, Hassman DR, Madder RD, et al. Repaglinide versus nateglinide monotherapy: a randomized, multicenter study. Diabetes Care 2004; 27:1265-1270.
42. Yki-Jarvinen, H. Thiazolidinediones. N Engl J Med 2004; 351:1106-1118.
43. Nissen, SE and Wolski k. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 2007; 356:2457-2471.
44. Home PD, Pocock SJ, Beck-Nielsen H, et al; RECORD Study Group. Rosiglitazone evaluated for cardiovascular outcomes-an interim analysis. N Engl J Med 2007; 357:28-38.
45. Dormandy JA, Charbonnel B, Eckland DJ, et al; PROactive investigators. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet 2005; 366:1279-1289.
46. Kahn SE, Haffner SM, Heise MA, et al; ADOPT Study Group. Glycemic durability of rosigli-tazone, metformin, or glyburide monotherapy. N Engl J Med 2006; 355:2427-2443.
47. http://www.fda.gov/medwatch/safety/2007/safety07.htm#actos. [Last accessed August 1, 2007].
48. Janghorbani M, Van Dam RM, Willett WC, et al. Systematic review of type 1 and type 2 diabetes mellitus and risk of fracture. Am J Epidemiol 2007; 166:495-505.
49. Amori RE, Lau J, Pittas AG. Efficacy and safety of incretin therapy in type 2 diabetes: systematic review and meta-analysis. JAMA 2007; 298:194-206.
50. Holst JJ, Deacon CF. Inhibition of the activity of dipeptidyl-peptidase IV as a treatment for type 2 diabetes. Diabetes 1998; 47:1663-1670.
51. Hollander PA, Levy P, Fineman MS, et al. Pramlintide as an adjunct to insulin therapy improves long-term glycemic and weight control in patients with type 2 diabetes: a 1-year randomized controlled trial. Diabetes Care 2003; 26:784-790.
52. Colagiuri S, Cull CA, Holman RR. Are lower fasting plasma glucose levels at diagnosis of type 2 diabetes associated with improved outcomes?: U.K. Prospective Diabetes Study 61. Diabetes Care 2002; 25:1410-1417.
53. DeFronzo RA, Ratner RE, Han J, et al. Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes. Diabetes Care 2005; 28:1092-1100.
54. Fonseca V, Rosenstock J, Patwardhan R, et al. Effect of metformin and rosiglitazone combination therapy in patients with type 2 diabetes mellitus: a randomized controlled trial. JAMA 2000; 283:1695-1702.
55. Charbonnel B, Karasik A, Liu J, et al; Sitagliptin Study 020 Group. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone. Diabetes Care 2006; 29(12):2638-2643.
56. Triplitt C, Glass L, Miyazaki Y, et al. Comparison of glargine insulin versus rosiglitazone addition in poorly controlled type 2 diabetic patients on metformin plus sulfonylurea. Diabetes Care 2006; 29:2371-2377.
57. Heine RJ, Van Gaal LF, Johns D, et al. for the GWAA Study Group. Exenatide versus insulin glargine in patients with suboptimally controlled type 2 diabetes. Ann Intern Med 2005; 143:559-569.
58. Schwartz S, Sievers R, Strange P, et al. INS-2061 Study Team. Insulin 70/30 mix plus metformin versus triple oral therapy in the treatment of type 2 diabetes after failure of two oral drugs: efficacy, safety, and cost analysis. Diabetes Care 2003; 26:2238-2243.
59. Grant RW, Buse JB, Meigs JB. Quality of diabetes care in U.S. academic medical centers: low rates of medical regimen change. Diabetes Care 2005; 28:337-442.
60. AACE Diabetes Mellitus Clinical Practice Guidelines Task Force. American Association of Clinical Endocrinologists medical guidelines for clinical practice for the management of diabetes mellitus. Endocr Pract 2007; 13(Suppl 1):1-68.
61. Nathan DM, Buse JB, Davidson MB, et al. Management of hyperglycemia in type 2 diabetes: A consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2006; 29:1963-1972.
62. Ryan EA, Imes S, Wallace C. Short-term intensive insulin therapy in newly diagnosed type 2 diabetes. Diabetes Care 2004; 27:1028-1032.
63. Li Y, Xu W, Liao Z, et al. Induction of long-term glycemic control in newly diagnosed type 2 diabetic patients is associated with improvement of beta-cell function. Diabetes Care. 2004; 27:2597-2602.
64. Ceglia L, Lau J, Pittas AG. Meta-analysis: efficacy and safety of inhaled insulin therapy in adults with diabetes mellitus. Ann Intern Med 2006; 145:665-675.
65. AACE Diabetes Mellitus Clinical Practice Guidelines Task Force. American Association of Clinical Endocrinologists medical guidelines for clinical practice for the management of diabetes mellitus. Endocr Pract 2007; 13(Suppl 1):1-68.
66. Plank J, Siebenhofer A, Berghold A, et al. Systematic review and meta-analysis of short-acting insulin analogues in patients with diabetes mellitus. Arch Intern Med 2005; 165:1337-1344.
67. Siebenhofer A, Plank J, Berghold A, et al. Short acting insulin analogues versus regular human insulin in patients with diabetes mellitus. Cochrane Database Syst Rev 2004(2):CD003287.
68. Gough SC. A review of human and analogue insulin trials. Diabetes Res Clin Pract 2007; 77:1-15.
69. Horvath K, Jeitler K, Berghold A, et al. Long-acting insulin analogues versus NPH insulin (human isophane insulin) for type 2 diabetes mellitus. Cochrane Database Syst Rev 2007(2):CD005613.
70. Meneghini LF, Rosenberg KH, Koenen C, et al. Insulin detemir improves glycaemic control with less hypoglycaemia and no weight gain in patients with type 2 diabetes who were insulin naive or treated with NPH or insulin glargine: clinical practice experience from a German subgroup of the PREDICTIVE study. Diabetes Obes Metab 2007; 9:418-427.
71. Philis-Tsimikas A, Charpentier G, Clauson P, et al. Comparison of once-daily insulin detemir with NPH insulin added to a regimen of oral antidiabetic drugs in poorly controlled type 2 diabetes. Clin Ther 2006; 28:1569-1581.
72. Raslova K, Tamer SC, Clauson P, et al. Insulin detemir results in less weight gain than NPH insulin when used in basal-bolus therapy for type 2 diabetes mellitus, and this advantage increases with baseline body mass index. Clin Drug Investig 2007; 27:279-285.
73. UK Hypoglycaemia Study Group. Risk of hypoglycaemia in types 1 and 2 diabetes: effects of treatment modalities and their duration. Diabetologia 2007; 50:1140-1147.
74. Fritsche A, Schweitzer MA, Häring HU. Glimepiride combined with morning insulin glargine, bedtime neutral protamine hagedorn insulin, or bedtime insulin glargine in patients with type 2 diabetes. A randomized, controlled trial. Ann Intern Med 2003; 138:952-959.
75. Janka HU, Plewe G, Riddle MC, et al. Comparison of basal insulin added to oral agents versus twice-daily premixed insulin as initial insulin therapy for type 2 diabetes. Diabetes Care 2005; 28:254-259.
76. Riddle MC, Rosenstock J, Gerich J; Insulin Glargine 4002 Study Investigators. The treat-to-target trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients. Diabetes Care 2003; 26:3080-3086.
77. Yki-Jarvinen H. Combination therapies with insulin in type 2 diabetes. Diabetes Care 2001; 24:758-767.
78. Yki-Jarvinen H, Kauppinen-Mäkelin R, Tiikkainen M, et al. Insulin glargine or NPH combined with metformin in type 2 diabetes: the LANMET study. Diabetologia 2006; 49:442-451.
79. Yki-Jarvinen H, Ryysy L, Nikkilä K, et al. Comparison of bedtime insulin regimens in patients with type 2 diabetes mellitus. A randomized, controlled trial. Ann Intern Med 1999; 130:389-396.
80. Cusi K, Cunningham GR, Comstock J P. Safety and efficacy of normalizing fasting glucose with bedtime NPH insulin alone in NIDDM. Diabetes Care 1995; 18:843-851.
81. Raskin P, Allen E, Hollander P, et al; INITIATE Study Group. Initiating insulin therapy in type 2 diabetes: a comparison of biphasic and basal insulin analogs. Diabetes Care 2005; 28:260-265.
82. Heine RJ, Van Gaal LF, Johns D, et al; GWAA Study Group. Exenatide versus insulin glargine in patients with suboptimally controlled type 2 diabetes: a randomized trial. Ann Intern Med 2005; 143:559-569.
83. Yki-Jarvinen H, Kauppila M, Kujansuu E, et al. Comparison of insulin regimens in patients with non-insulin-dependent diabetes mellitus. N Engl J Med 1992; 327:1426-1433.
84. Riddle MC, Schneider J. Beginning insulin treatment of obese patients with evening 70/30 insulin plus glimepiride versus insulin alone. Glimepiride Combination Group. Diabetes Care 1998; 21:1052-1057.
85. Garber AJ, Wahlen J, Wahl T, et al. Attainment of glycaemic goals in type 2 diabetes with once-, twice-, or thrice-daily dosing with biphasic insulin aspart 70/30 (The 1-2-3 study). Diabetes Obes Metab 2006; 8:58-66.
86. Ligthelm RJ, Mouritzen U, Lynggaard H, et al. Biphasic insulin aspart given thrice daily is as efficacious as a basal-bolus insulin regimen with four daily injections: a randomised open-label parallel group four months comparison in patients with type 2 diabetes. Exp Clin Endocrinol Diabetes 2006; 114:511-519.
87. Davies M, Storms F, Shutler S, et al; ATLANTUS Study Group. Improvement of glycemic control in subjects with poorly controlled type 2 diabetes: comparison of two treatment algorithms using insulin glargine. Diabetes Care 2005; 28:1282-1288.
88. Yki-Jarvinen H, Juurinen L, Alvarsson M, et al. Initiate Insulin by Aggressive Titration and Education (INITIATE): a randomized study to compare initiation of insulin combination therapy in type 2 diabetic patients individually and in groups. Diabetes Care 2007; 30:1364-1369.
89. Schwartz S, Sievers R, Strange P, et al; INS-2061 Study Team. Insulin 70/30 mix plus metformin versus triple oral therapy in the treatment of type 2 diabetes after failure of two oral drugs: efficacy, safety, and cost analysis. Diabetes Care 2003; 26:2238-2243.
90. Triplitt C, Glass L, Miyazaki Y, et al. Comparison of glargine insulin versus rosiglitazone addition in poorly controlled type 2 diabetic patients on metformin plus sulfonylurea. Diabetes Care 2006; 29:2371-2377.
91. Strowig SM, Raskin P, Combination therapy using metformin or thiazolidinediones and insulin in the treatment of diabetes mellitus. Diabetes Obes Metab 2005; 7:633-641.
92. Peyrot M, Rubin RR, Lauritzen T, et al. The International DAWN Advisory Panel. Resistance to insulin therapy among patients and providers: results of the cross-national Diabetes Attitudes, Wishes, and Needs (DAWN) study. Diabetes Care 2005; 28:2673-2679.
93. Rubin RR, Peyrot M. Quality of life, treatment satisfaction, and treatment preference associated with use of a pen device delivering a premixed 70/30 insulin aspart suspension (aspart protamine suspension/soluble aspart) versus alternative treatment strategies. Diabetes Care 2004; 27:2495-2497.
94. Freemantle N, Blonde L, Duhot D, et al. Availability of inhaled insulin promotes greater perceived acceptance of insulin therapy in patients with type 2 diabetes. Diabetes Care 2005; 28:427-428.
95. Brownlee M. Biochemistry and molecular cell biology of diabetic complications. Nature 2001; 414:813-820.
96. King GL, Brownlee M. The cellular and molecular mechanisms of diabetic complications. Endocrinol Metab Clin North Am 1996; 25:255-270.
97. Vasudevan AR, Burns A, Fonseca VA. The effectiveness of intensive glycemic control for the prevention of vascular complications in diabetes mellitus. Treat Endocrinol 2006; 5:273-286.
98. Fonseca V, Desouza C, Asnani S, Jialal I. Nontraditional risk factors for cardiovascular disease in diabetes. Endocr Rev 2004; 25:153-175.
99. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. N Engl J Med 1993; 329:977-986.
100. Ohkubo Y, Kishikawa H, Araki E, et al. Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus - a randomized prospective 6-year study. Diabetes Res Clin Pract 1995; 28:103-117.
101. UK Prospective Diabetes Study Group. Tight blood pressure control and risk of mac-rovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ 1998; 317:703-713.
102. The Writing Team for the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group. Effect of intensive therapy on the micro-vascular complications of type 1 diabetes mellitus. JAMA 2002; 287:2563-2569.
103. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) group. Lancet 1998; 352(9131):837-853.
104. American Diabetes Association. Standards of medical care in diabetes - 2007. Diabetes Care 2007; Jan 30(Suppl 1):S4-S41.
105. Borch-Johnsen K,. Feldt-Rasmussen B, Strandgaard S, Schroll M, Jensen IS. Urinary albumin excretion: an independent predictor of ischemic heart disease. Arterioscler Thromb Vasc Biol 1999; 19:19920-1997.
106. Romundstad S, Holmen J, Kvenild K, Hallan H, Ellekjaer H. Microalbmninuria and all-cause mortality in 2, 089 apparently healthy individuals: A 4.4-year follow-up study. The Nordtrondelag Health Study (HUNT), Norway. Am J Kidney Dis 2003; 4:466-473.
107. Scheen AJ. Prevention of type 2 diabetes mellitus through inhibition of the renin-angiotensin system. Drugs 2004; 64:2537-2565.
108. Levey AS, Bosch JP, Lewis JB, et al. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med 1999; 130:461-470.
109. Jawa A Kcomt J, Fonseca VA. Diabetic nephropathy and retinopathy. Med Clin North Am 2004; 88:1001, 36,. xi.
110. Joss JD. Tricyclic antidepressant use in diabetic neuropathy. Ann Pharmacother 1999; 33:996-1000.
111. Max MB, Lynch SA, Muir J, et al. Effects of desipramine, amitriptyline, and fluoxetine on pain in diabetic neuropathy. N Engl J Med 1992; 326:1250-1256.
112. McQuay HJ, Tramèr M, Nye BA, et al. A systematic review of antidepressants in neuropathic pain. Pain 1996; 68:217-227.
113. Backonja M, Beydoun A, Edwards KR, et al. Gabapentin for the symptomatic treatment of painful neuropathy in patients with diabetes mellitus: a randomized controlled trial. JAMA 1998; 280:1831-1836.
114. Rosenstock J, Tuchman M, LaMoreaux L, et al. Pregabalin for the treatment of painful diabetic peripheral neuropathy: a double-blind, placebo-controlled trial. Pain 2004; 110:628-638.
115. Richter RW, Portenoy R, Sharma U, et al. Relief of painful diabetic peripheral neuropathy with pregabalin: a randomized, placebo-controlled trial. J Pain 2005; 6:253-260.
116. Goldstein DJ, Lu Y, Detke MJ, et al. Duloxetine vs. placebo in patients with painful diabetic neuropathy. Pain 2005; 116:109-118.
117. Fight against diabetes and heart disease link intensifies: more efforts needed to help people with diabetes manage the "abcs of diabetes". Available at: http://diabetes.org/for-media/2004-press-releases/fight-diabetes. jsp. Last accessed September 2007.
118. The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin converting enzyme inhibitor or calcium channel blocker vs diuretic. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002; 288:1981-1997.
119. Boden WE. High-density lipoprotein cholesterol as an independent risk factor in cardiovascular disease: assessing the data from Framingham to the Veterans Affairs High-Density Lipoprotein Intervention Trial. Am J Cardiol 2000; 86:19L-22L.
120. Wackers FJ, Young LH, Inzucchi SE, et al. Detection of silent myocardial ischemia in asymptomatic diabetic subjects: the DIAD study. Diabetes Care 2004; 27:1954-1961.
121. Kitabchi AE, Umpierrez GE, Murphy MB, et al. Management of hyperglycemic crises in patients with diabetes. Diabetes Care 2001; 24:131-53.
122. Cryer PE, Davis SN, Shamoon H. Hypoglycemia in diabetes. Diabetes Care 2003; 26:1902-12.
123. International Diabetes Federation. Diabetes Education: A Right for All. Position Statement. Available at: www.idf.org/home/index.cfm?unode=A1205437- D4F1-40B3-B69D-2E536E0F62CB. Last accessed September 2007.
124. Mensing C, Boucher J, Cypress M, et al. National Standards for Diabetes Self-Management Education. Diabetes Care 2007; 30(Suppl 1):S96-S103.
125. National Institute of health. What we want to achieve through systems changes: patient-centered care: patient education. Available at: www.betterdiabetescare.nih.gov/WHATpatientcenteredcare.htm. Last accessed September 2007.
126. Kronsbein P, Jorgens V, Muhlhauser I, et al. Evaluation of a structured treatment and teaching programme on non-insulin dependent diabetes. Lancet 1988; 2:1407-1411.
127. Berger M, Muhlhauser I. Diabetes care and patient-oriented outcomes. JAMA 1999; 281:1676-1678.
128. American Association of Diabetes Educators. AADE position statement. Individualization of diabetes self-management education. Diabetes Educ 2007; 33:45-49.
129. Piette, JD. The effectiveness of diabetes self-management education: an overview of published studies. Available at: www.eatlas.idf.org/webdata/docs/ Effectiveness%20of%20 diabetes%20education.pdf. Last accessed September 2007.
130. National Institute for Clinical Excellence. Guidance on the use of patient-education models for diabetes. April 2003. Available at: www.nice.org.uk/pdf/FAD-patient-educationmod-els-diabetes.pdf. Last accessed September 2007.
131. Agency for Healthcare Research and Quality. Improving care for diabetes patients through intensive therapy and a team approach. Available at: www.ahrq.gov/research/diabria/diabria.pdf. Last accessed September 2007.
132. Dailey, G. Assessing glycemic control with self-monitoring of blood glucose and hemoglobin A1c measurements. Mayo Clin Proc 2007; 82:229-236.
133. Renard E. Monitoring glycemic control: the importance of self-monitoring of blood glucose. Am J Med 2005; 118:12-19.
134. Murata GH, Adam, KD, Shah JH, et al. Intensified blood glucose monitoring improves glycemic control in stable, insulin-treated veterans with type 2 diabetes. Diabetes Care 2003; 26:1759-1763.
135. Farmer A, Wade A, Goyder E, et al. Impact of self monitoring of blood glucose in the management of patients with non-insulin treated diabetes: open parallel group randomized trial. BMJ 2007; 335:132.
136. Austin MM. Importance of self-care behaviors in diabetes management. US Endocrine Review 2005; 16-21.
137. Nagelkerk J, Reick K, Meengs L. Perceived barriers and effective strategies to diabetes self-management. J Adv Nurs 2006; 54:151-158.
138. Glasgow RE, Hampson SE, Strycker LA, et al. Personal-model beliefs and social-environmental barriers related diabetes self-management. Diabetes Care 1997; 20:556-561.
139. Lauritzen T, Zoffmann V. Understanding the psychological barriers to effective diabetes therapy. Diabetes Voice 2004; 49:16-18.
140. Bayliss EA, Steiner JF, Fernald DH, et al. Descriptions of barriers to self-care by persons with comorbid chronic diseases. Ann Fam Med 2003; 1:15-21.
141. Ciechanowski PS, Katan WJ, Russo JE. Depression and diabetes. Arch Intern Med 2000; 160:3278-3285.
142. Polonsky WH, Earles J, Christensen R, et al. Integrating medical management with diabetes self-management training. Diabetes Care 2003; 26:3048-3053.
143. Nwasuruba C, Khan M, Egede LE. Racial/ethnic differences in multiple self-care behaviors in adults with diabetes. J Gen Intern Med 2007; 22:115-120.
144. Sarkar U, Fisher L, Schillinger D. Is self-efficacy associated with diabetes self-management across race/ethnicity and health literacy? Diabetes Care 2006; 29:823-829.
145. Aljasem LI, Peyrot M, Wissow L, et al. The impact of barriers and self-efficacy on self-care behaviors in type 2 diabetes. Diabetes Educ 2001; 27:393-404.
146. Polonsky WH. Encouraging effective self-management in diabetes. US Endocrine Disease 2006. Available at: www.touchbriefings.com/cdps/cditem.cfm? nid=1815&cid=5. Last accessed September 2007.
147. Del Prato S, Felton AM, Munro N, et al; Global Partnership for Effective Diabetes Management. Improving glucose management: ten steps to get more patients with type 2 diabetes to glycaemic goal. Int J Clin Pract 2005; 59:1345-1355.
148. Funnell M, Anderson RM. Empowerment and self-management of diabetes. Clinical Diabetes 2004; 22:123-127.